Arcus And Gilead Keep TIGIT Dream Alive Despite Trial Shortcomings
Still In The Game After Mixed Phase II Results
Executive Summary
Arcus and Gilead’s latest Phase II readout has produced mixed signals, but some analysts are reassured about the potential of domvanalimab and the wider TIGIT field.
You may also be interested in...
Gilead Increases Investment In Arcus; Firms Abandon Chemo-Free Combo Study
With a $320m equity investment, Gilead will now own 33% of partner Arcus, which it said reinforces its optimism around the anti-TIGIT class for oncology.
As Gilead’s PD-1/TIGIT Trial Falls Short, Oncologists Say Better Biomarkers Needed
The ARC-7 trial showed a progression-free survival benefit in NSCLC, but the PFS benefit for zimberelimab/domvanalimab wasn’t as big as analysts and oncologists had hoped.
Gilead Adds Inflammation Targets To Its 2020 R&D Collaboration With Arcus
Deal Snapshot: Already partnered on an anti-TIGIT drug and other immuno-oncology candidates, the firms will team up further on four targets in inflammatory disease.